Tm Bioscience ready to consider sale or merger
This article was originally published in Clinica
Tm Bioscience, the Toronto-based developer of DNA-based tests, says it would consider a sale or merger of its business as part of an exploration of ways to increase its value to shareholders. The company has appointed investment banks Leerink & Swann, of Boston, Massachusetts, and Westwind Partners, of Toronto, to help assess its options.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.